# A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis

> **NCT01723254** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 190 (actual)

## Conditions studied

- Allergic Rhinitis

## Interventions

- **BIOLOGICAL:** IGE-1
- **BIOLOGICAL:** IGE-2
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT01723254
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01723254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01723254, "A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01723254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*